Drug Trial Radar · NCT01482156
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jan 2012
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 30, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors. 2. Dose-expansion: to assess safety and tolerability of RAD001 and BEZ235 at the MTD in patients with ER+/HER2- metastatic breast cancer and metastatic renal cell cancer
Conditions
- Advanced Solid Tumors
- Metastatic Breast Cancer
- Metastatic Renal Cell Carcinoma
Interventions
RAD001 + BEZ235Drug
RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Probability of a Dose Limiting Toxicity (DLT) by the end of the first treatment cycle (DLT)Time frame: First treatment cycle (28 days)
- Incidence of DLT in patients by the end of the first treatment cycle in the co-administration of RAD001 and BEZ235Time frame: First treatment cycle (28 days)
- Number of participants with adverse events and serious adverse events.Time frame: 12 months
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas
Washington University School of Medicine Washington University (16)
St Louis, Missouri
Medical University of South Carolina SC
Charleston, South Carolina
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Montellier Cedex 5, France
Novartis Investigative Site
Verona, VR, Italy
Novartis Investigative Site
Auckland, New Zealand
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
High Heaton, Newcastle Upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.